Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of atrasentan in immunoglobulin A nephropathy (IgAN) (4 cohorts), sponsored by Novartis. Primary endpoint: Change From Baseline in Proteinuria at 36 weeks. Started Aug 2026; status: recruiting.
02
Drugs
atrasentan
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07498335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498335.